Status:
UNKNOWN
To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib.
Lead Sponsor:
Peking University
Conditions:
GIST
Eligibility:
All Genders
18+ years
Brief Summary
To compare the efficacy of surgery followed by sunitinib with surgery followed by imatinib in GIST patients with progression on imatinib;To investigate the optimal therapy after surgery in GIST patien...
Detailed Description
Primary Endpoint: To evaluate the progression free survival of the patients with progression receiving surgery followed by sunitinib therapy comparing with surgery followed by imatinib Secondary Endpo...
Eligibility Criteria
Inclusion
- .Histopathological diagnosis of metastatic GIST.
- . After the treatment of imatinib, imatinib 400mg/day after treatment, the tumor generalized.
- . Patients with generalized progress were satisfied with tumor reduction after imatinib resistance for various reasons.
- at least 1 month after surgery for imatinib treatment or sunitinib treatment.
- at least one imaging assessment was received after surgery.
- . Complete clinical data and follow-up data.
Exclusion
- . Before operation, he was treated with sunitinib
- . Patients receiving tumor reduction were not satisfied with the standard of the reduction of tumor.
- . The treatment of imatinib or sunitinib after surgery was less than 1 month.
- . Incomplete clinical data or follow-up data.
Key Trial Info
Start Date :
June 2 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 8 2018
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03424876
Start Date
June 2 2017
End Date
August 8 2018
Last Update
March 1 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142